文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-FAP-2286:一种用于多种类型转移性癌症患者PET/CT显像的新型有前景的诊疗一体化方法

[68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET/CT imaging in patients with various type of metastatic cancers.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-20

这项前瞻性研究纳入21例多种类型转移性癌症患者,静脉注射[68Ga]Ga-FAP-2286后1小时行全身PET/CT显像并计算SUVmax与靶本比(TBR)。所有患者(100%,21/21)肿瘤病灶均显示明显摄取,且无论肿瘤起源或病灶类型均可见摄取;4小时随访内未见药物相关药理作用,作者认为其是用于转移性癌症诊断的有前景的FAP衍生物,并被视为晚期转移性癌症患者的潜在治疗用化合物。

要点

  • 21例多种转移性癌症患者中,[68Ga]Ga-FAP-2286 PET/CT显示全部患者(100%,21/21)肿瘤病灶有明显摄取。
  • 无论肿瘤起源为上皮或间皮,也无论局部复发、远处复发或转移病灶,PET/CT均显示[68Ga]Ga-FAP-2286摄取。
  • 诊断过程前、中、后4小时随访观察心率、血压、体温等生命体征,未见药物相关药理作用征象。

核心结论

  • 这些数据提示[68Ga]Ga-FAP-2286是一种有前景的FAP衍生物,可用于转移性癌症的有效诊断,并被视为晚期转移性癌症患者的潜在治疗用化合物。

研究设计与样本

  • 前瞻性研究纳入21例平均年龄51.9岁的多种类型残余和转移性癌症患者,其中6例转移性肉瘤、14例腺癌(8例乳腺、2例直肠、2例肺、2例胰腺、1例甲状腺)。
  • 患者接受[68Ga]Ga-FAP-2286 PET/CT显像,给药后1小时行全身扫描视觉评估与PET/CT半定量分析,计算肿瘤病灶SUVmax与靶本比(TBR)。

主要发现

  • 所有患者(100%,21/21)肿瘤病灶均显示[68Ga]Ga-FAP-2286明显摄取。
  • 无论肿瘤起源为上皮或间皮,也无论病灶为局部复发、远处复发或转移,PET/CT均显示[68Ga]Ga-FAP-2286摄取。
  • 诊断过程前、中、后4小时随访观察心率、血压、体温等生命体征,所有患者接受[68Ga]Ga-FAP-2286 PET/CT扫描均未见药物相关药理作用征象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibroblast activation protein (FAP) has emerged as a promising target for diagnosis and therapeutic intervention due to high expression and accumulation in the stromal compartments of a variety of malignant tumors. FAP-2286 utilizes cyclic peptides with FAP-binding characteristics to enhance the retention of the imaging agent within tumors, in contrast to the small-molecule FAP inhibitors (FAPI) like FAPI-04/46. The aim of this study was to quantify the tumor uptake of [68Ga] Gallium-FAP-2286 within primary solid tumors, adjacent excised tissues, and metastatic lesions. METHODS: In this prospective study, 21 patients (average age 51.9) with various diagnoses of remaining and metastatic cancers participated. Among them, six had metastatic sarcoma, and 14 had adenocarcinoma, including eight breast, two rectum, two lung, two pancreas, and one thyroid cases. The patients underwent a [68Ga]Ga-FAP-2286 PET/CT scan. An hour post-administration of [68Ga]Ga-FAP-2286, a visual assessment of whole body scans and semi-quantification of the PET/CT results were carried out. The standardized uptake values (SUV)max of [68Ga]Ga-FAP-2286 in tumor lesions and the tumor-to-background ratio (TBR) were then calculated. RESULTS: The vital signs of the patients, such as heart rate, blood pressure, and temperature, were observed before, during, and after the diagnostic procedure during the 4-h follow-up. All individuals underwent the [68Ga]Ga-FAP-2286 PET/CT scans without any signs of drug-associated pharmacological effects. The PET/CT scans displayed substantial absorption of [68Ga]Ga-FAP-2286 in tumor lesions in all patients (100% (21/21)). Irrespective of the tumors' origins (epithelial or mesothelium) and whether they exhibited local recurrence, distant recurrence, or metastatic lesions, the PET/CT scans revealed the uptake of [68Ga]Ga-FAP-2286 in these lesions. CONCLUSION: Overall, these data suggest that [68Ga]Ga-FAP-2286 is a promising FAP derivative for efficient metastatic cancer diagnosis and being considered as a potential compound for therapeutic application in patients with advanced metastatic cancers.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Banihashemian SS, Divband G, Pirayesh E, et al. [68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET/CT imaging in patients with various type of metastatic cancers. Eur J Nucl Med Mol Imaging. 2024. PMID: 38376804. doi:10.1007/s00259-024-06635-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。